Healios K.K. (4593.T)
JPY 323.0
(0.94%)
JPY 323.0
(0.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.19 Billion JPY | -2068.32% |
| 2022 | -101 Million JPY | 96.81% |
| 2021 | -3.17 Billion JPY | -25.79% |
| 2020 | -2.52 Billion JPY | 60.91% |
| 2019 | -6.44 Billion JPY | 27.8% |
| 2018 | -8.92 Billion JPY | 46.44% |
| 2017 | -16.66 Billion JPY | -212.94% |
| 2016 | -5.32 Billion JPY | 42.07% |
| 2015 | -9.19 Billion JPY | -372.32% |
| 2014 | -1.94 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.53 Billion JPY | -61.28% |
| 2024 Q2 | -2.79 Billion JPY | 20.87% |
| 2023 Q2 | 186 Million JPY | 1030.0% |
| 2023 Q4 | -2.19 Billion JPY | 12.01% |
| 2023 FY | -2.19 Billion JPY | -2068.32% |
| 2023 Q3 | -2.48 Billion JPY | -1438.17% |
| 2023 Q1 | -20 Million JPY | 80.2% |
| 2022 Q3 | 216 Million JPY | 14.29% |
| 2022 Q2 | 189 Million JPY | 115.71% |
| 2022 Q1 | -1.2 Billion JPY | 62.05% |
| 2022 FY | -101 Million JPY | 96.81% |
| 2022 Q4 | -101 Million JPY | -146.76% |
| 2021 Q1 | -786 Million JPY | 68.81% |
| 2021 FY | -3.17 Billion JPY | -25.79% |
| 2021 Q4 | -3.17 Billion JPY | 37.93% |
| 2021 Q2 | 353 Million JPY | 144.91% |
| 2021 Q3 | -5.1 Billion JPY | -1546.74% |
| 2020 Q1 | -6.73 Billion JPY | -4.45% |
| 2020 Q2 | -4.67 Billion JPY | 30.55% |
| 2020 Q3 | -3.82 Billion JPY | 18.2% |
| 2020 Q4 | -2.52 Billion JPY | 34.12% |
| 2020 FY | -2.52 Billion JPY | 60.91% |
| 2019 Q3 | -7.46 Billion JPY | -22.41% |
| 2019 FY | -6.44 Billion JPY | 27.8% |
| 2019 Q2 | -6.09 Billion JPY | 19.6% |
| 2019 Q1 | -7.58 Billion JPY | 15.09% |
| 2019 Q4 | -6.44 Billion JPY | 13.6% |
| 2018 FY | -8.92 Billion JPY | 46.44% |
| 2018 Q2 | -12 Billion JPY | 1.51% |
| 2018 Q4 | -8.92 Billion JPY | 17.06% |
| 2018 Q1 | -12.18 Billion JPY | 26.9% |
| 2018 Q3 | -10.76 Billion JPY | 10.31% |
| 2017 Q2 | -13.6 Billion JPY | -101.89% |
| 2017 Q3 | -13.92 Billion JPY | -2.34% |
| 2017 Q1 | -6.74 Billion JPY | -26.54% |
| 2017 Q4 | -16.66 Billion JPY | -19.69% |
| 2017 FY | -16.66 Billion JPY | -212.94% |
| 2016 FY | -5.32 Billion JPY | 42.07% |
| 2016 Q2 | -6.62 Billion JPY | -13.24% |
| 2016 Q1 | -5.84 Billion JPY | 36.41% |
| 2016 Q4 | -5.32 Billion JPY | 10.82% |
| 2016 Q3 | -5.97 Billion JPY | 9.8% |
| 2015 Q4 | -9.19 Billion JPY | 3.67% |
| 2015 Q2 | -8.78 Billion JPY | 0.0% |
| 2015 FY | -9.19 Billion JPY | -372.32% |
| 2015 Q3 | -9.54 Billion JPY | -8.69% |
| 2014 FY | -1.94 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 394.847% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -93.131% |
| GNI Group Ltd. | -17.93 Billion JPY | 87.788% |
| Linical Co., Ltd. | -4.46 Billion JPY | 50.933% |
| Trans Genic Inc. | -221.16 Million JPY | -890.193% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 50.16% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 54.28% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 252.769% |
| AnGes, Inc. | -3.79 Billion JPY | 42.334% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -420.429% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 108.792% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -339.623% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -369.607% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 19.073% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -15.983% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -122.982% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 35.532% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -111.685% |
| Kidswell Bio Corporation | 343.58 Million JPY | 737.389% |
| PeptiDream Inc. | 3.29 Billion JPY | 166.525% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -125.171% |
| Ribomic Inc. | -2.09 Billion JPY | -4.298% |
| SanBio Company Limited | -3.78 Billion JPY | 42.212% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -131.78% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 16.544% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -54.545% |
| StemRIM | -8.41 Billion JPY | 73.96% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 53.24% |
| FunPep Company Limited | -1.79 Billion JPY | -22.116% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -2.505% |
| Stella Pharma Corporation | -1.11 Billion JPY | -95.64% |
| TMS Co., Ltd. | -3.44 Billion JPY | 36.46% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 60.581% |
| Cuorips Inc. | -5.56 Billion JPY | 60.619% |
| K Pharma,Inc. | -3.26 Billion JPY | 32.954% |
| Takara Bio Inc. | -32.2 Billion JPY | 93.199% |
| ReproCELL Incorporated | -2.93 Billion JPY | 25.486% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -231.336% |
| StemCell Institute Inc. | -2.83 Billion JPY | 22.799% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -5.984% |
| CellSeed Inc. | -2.01 Billion JPY | -8.845% |